达利珠单抗和OKT3预防肾移植术后急性排斥反应的比较

目的　比较达利珠单抗和OKT3预防肾移植术后早期急性排斥反应的效果。方法　肾移植受者在使用环孢素A(或他克莫司 )、霉酚酸酯及激素预防急性排斥反应的基础上加用达利珠单抗 (42例 )或OKT3(12 8例 ) ,观察 2个组肾移植术后 3个月内急性排斥反应发生率。结果　肾移植术后 3个月内 ,使用达利珠单抗者急性排斥反应发生率为 2 .4 % ,明显低于使用OKT3者的13.3% (P <0 .0 5 ) ,且前者无耐激素者 ,急性排斥反应的发生时间推迟 ,血肌酐恢复正常的时间也早于使用OKT3者。结论　达利珠单抗预防肾移植术后急性排斥反应的效果优于OKT3。

Comparison of the efficacy of Simulect and OKT3 for prevention of acute renal allograft rejection

Objective To compare the clinical efficacy of Simulect and OKT3 for prevention of acute renal allograft rejection. Methods A total of 170 first cadaveric kidney transplant recipients were randomized to receive Simulect (Simulect group, n=42) or OKT3 (OKT3 group, n=128) subject to triple immunosuppression therapy (CsA/FK506, Cellcept and prednisone). The incidence of acute rejection was observed in both groups.Results Simulect group had less frequent incidence of acute rejection ( 2.4 % versus 13.2 %, P< 0.05) during the first 3 months after renal transplantation compared to OKT3 group. The 3-month person/graft survival rate in Simulect group and OKT3 group was 100 % and 99.2 %, respectively, with the difference being not statistical.Conclusion Simulect is an ideal immunosuppressive agent which is more effective for prevention of acute renal transplant allograft rejection than OKT3.